Exclusive: WHO set to back use of weight-loss drugs for adults globally, raises cost issue
LONDON, May 1 (Reuters) - The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first time, a memo reviewed by Reuters on Thursday shows, marking a shift in its approach to treating the global health problem.
The UN agency also called for strategies to improve access to the treatment in low- and middle-income countries.
Keep up with the latest medical breakthroughs and healthcare trends with the Reuters Health Rounds newsletter. Sign up here.
More than a billion people now have obesity worldwide, according to the WHO, and around 70% of them live in low and middle-income countries, the World Bank estimates.
The wildly popular obesity drugs - Wegovy developed by Novo Nordisk (NOVOb.CO), opens new tab and Zepbound by Eli Lilly (LLY.N), opens new tab - are known as GLP-1 receptor agonists, which mimic the activity of a hormone that slows digestion and helps people feel full for longer. In clinical trials, people lost 15% to 20% of their body weight, depending on the drug.
The drugs have been launched in the United States and other high-income countries like Germany and Britain.
But they can cost over $1,000 a month, and studies suggest people may have to take the drugs for the rest of their lives to keep the weight off.
The WHO, Eli Lilly and Novo Nordisk were not immediately available for comment.
The WHO's conditional recommendation will be officially released in August, as part of new guidelines on treating obesity. It is also working on separate guidelines for children and adolescents.
Separately, WHO experts will also meet next week to decide whether to include the GLP-1 drugs in the agency's essential medicines list - both to treat obesity and type 2 diabetes.
The WHO's essential medicines list is a catalogue of the drugs that should be available in all functioning health systems, and it can help make drugs more widely available in poorer countries, as experts say happened in 2002 when HIV drugs were included.
In 2023, the experts decided against adding obesity drugs to the list, with WHO saying more evidence was needed on their long-term clinical benefit.
However, in the new memo recommending their use as a treatment, the agency says it supports including them on the list this time round.
Still, the WHO also raises concerns over the cost of the drugs and calls for longer-term studies on cost-effectiveness "across all settings, including LMICs" (low- and middle-income countries).
"The same mechanisms that are used in large-scale medicine access programmes may need to be adopted," to improve access, the WHO adds, such as tiered pricing or pooled procurement.
But it also notes that the active ingredient in one of the newer drugs, semaglutide - used in Novo's Wegovy - comes off patent in some markets next year.
Several companies are planning to launch cheaper generic versions of the drugs then. Liraglutide, the active ingredient in the older generation of drugs, is already available as a lower-cost generic drug, with products approved in the U.S. and Europe, the memo adds.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Daily Mail
32 minutes ago
- Daily Mail
'After taking Mounjaro, my life fell apart': Women reveal disturbing side effects from jab that started within days
Women have reported terrifying mental health side effects after taking Mounjaro—the popular weight-loss injection used by thousands of people in the UK. Some describe sudden panic attacks, crippling anxiety and a sensation of 'tugging in the brain' after starting the drug. Mounjaro, along with similar treatments such as Ozempic and Wegovy, can help dieters lose up to 15 per cent of their body weight in a year. An estimated 1.5 million Britons used weight-loss jabs in March 2025 alone—and the new wave of jabs have been hailed as a breakthrough in the fight against obesity. But growing numbers of patients say they have experienced unexpected mental health symptoms—including insomnia, tremors, shortness of breath and tinnitus. Although these are not currently listed as official side effects for any of the three major jabs in the UK, an online support group for users suffering such symptoms has attracted more than 2,800 members. Three members—speaking anonymously to The Times—described the onset of debilitating anxiety, sleeplessness and panic attacks after starting Mounjaro. One said the anxiety felt like a kind of 'terror' she had never experienced before. The cases have prompted fresh questions over the safety profile of the medications as their use becomes more widespread. Charlotte Lloyd, 37, a social media manager from London and member of the online group, had anxiety symptoms so bad she found herself in A&E, The Times reported. Last autumn she gained weight during her fertility treatment, so she had a BMI high enough to qualify for the prescription weight-loss jab Mounjaro. While NHS access to the weight loss jab remain limited, the Mounjaro jab is widely available through online doctors and private clinics. To be eligible you must have a BMI of 30 or more, or a BMI between 27 and 30 (overweight) and a weight-related health condition such as prediabetes. Ms Lloyd said it was a simple process to access the jab privately through Asda Online Doctor by Zava—requiring her medical history, weight, height and some photographs. But her nightmare began within days of taking her first weekly 2.5mg dose, when she 'almost immediately' lost her appetite and started having difficulty sleeping. The next week after her second dose, she said 'the wheels fell completely off' when she 'stopped sleeping all together'. 'I tried sleeping pills, antihistamines—nothing worked. I may as well have been eating sweets. After two nights awake I started to feel like I was losing my mind,' she said. It wasn't just difficulty sleeping, three days after she started experiencing symptoms, she went to A&E when her 'heart was pounding nonstop'. In the hospital an ECG revealed her heart was above the normal resting heart rate for adults, which is between 60 and 100 beats per minute. But while it was 105bpm compared to her normal resting heart rate of 70bpm, the rhythm wasn't irregular, so she was discharged. 'I explained I hadn't slept in days and they basically told me to go home and have a bath,' she said. Despite still struggling to sleep, her GP was unable to help, as she had 'reached the limit of what she could prescribe'. Things got worse when she was hit by a series of panic attacks and tremors for five weeks—which she likened to 'swallowing an earthquake'. Although she had noted in her application for the medication she had experienced some anxiety and insomnia in the past, it was still approved. But the anxiety she now experienced she described as 'a physical terror I've never known. Like a switch had been flipped in my brain. 'I went into a constant state of fight-or-flight—like a bad drug trip that wouldn't end. I couldn't see how I was going to be able to survive it.' Initially signed off work unable to 'do anything' or even 'follow a conversation', she later resigned with her relationship ending that same week. The woman who said her life 'just fell apart', said: 'The way I see it, it's a roll of the dice as to how you're going to react to these drugs. 'If people knew that they could have potentially catastrophic mental and physical side-effects, they could make a more informed decision about taking them.' Ms Lloyd isn't the only one experiencing psychological side effects—another woman also found herself in A&E after taking the jab. Maria Edwards, ended up in hospital last year only 48 hours after taking her first dose of the Mounjaro jab. When her BMI was over 30, so she too qualified for the weight loss jab which got from the online doctor, MedExpress. 'I thought I was having a heart attack,' she said, but her scans, x-trays and bloods taken, all came back clear. She said: 'I've never had any mental health problems. I've never had a panic attack or anxiety. I've always been a laid-back person and now it's like everything is stressful. 'I get this thing that we've termed 'air hunger' where it's like I can't take a deep breath. If I'd have known Mounjaro could have mental health side-effects I never would have taken it.' The third woman, Julie Peters, a 31 year-old mother from Birmingham had a similar experience after getting the jab. She had a panic attack that lasted two hours on January 11, after taking the lowest dose, 2.5mg, of Mounjaro, once a week for two months. The mother went to A&E also thinking she was having a heart attack, but similarly she said: 'tests on my heart, kidneys, and for pancreatitis all came back clear. Ms Peters also described experiencing tremors, a 'tugging' sensation in her brain' and tinnitus—'The ringing in my ears has been constant, sometimes with multiple ringing sounds. 'The pressure and heaviness in my brain make me feel dull, disconnected and nauseous, and I also have a sensitivity to motion. 'I recently requested a brain MRI, and while the results came back normal, I am relieved yet uncertain about what to do next. It's incredibly suffocating,' she said. It follows a study published in January last year in the International Journal of Clinical Pharmacy which found 481 psychiatric events were linked to weight loss jabs. The 'seriousness of the adverse events warrants additional research' to explore the causual relationship,' said lead authors, Hajer Elkout and Mansour Tobaiqy. This was despite psychiatric events only accounting for 1.2 per cent of total reports associated with the active ingredients in weight loss medications. Anxiety, depression nor insomnia were listed as potential side effects by Asda Online Doctor by Zava or in the patient leaflet they refer patients to. The clinical governance team at the private pharmacist who stressed patient safety told The Times all applicants are required to give their medical history. This includes their GP details which they said enables the GP to inform them 'of any discrepancies or concerns they have with the prescription'. They added there are studies evidencing mental health can be improved with treatment, and no clinical-based-evidence of a negative impact 'they are aware of'. Last year a study published in the journal of Natural Medicine found taking semaglutide for weight loss or diabetes reduced the incidence of suicidal ideation. However, a more recent study found Ozempic and Mounjaro can raise the risk of depression and suicidal thoughts. However, Asda Online Doctor by Zava added: 'Our doctors, of course, will provide suitable advice to any particular patients of concern or who are managing complex mental health issues and may not be able to use the treatment appropriately alone. 'These patients, where necessary, will be signposted to their GPs for further support to manage their weight.' The manufacturers of Mounjaro, Eli Lilly, and of both Ozempic and Wegovy, Novo Nordisk told The Times patient safety was their top priority. 'We take any reports about patient safety seriously and actively monitor, evaluate and report safety information for all our medicines,' said Eli Lilly. With Novo Nordisk adding it welcomes: 'Independent research investigating the safety, efficacy and clinical utility of our products.' The two drug companies both highlighted that the UK regulatory agency had assessed the risk and benefits approving their respective drugs. Novo Nordisk added that independent analysis 'did not find an association between use of GLP-1RA medicines and the occurrence of increased risk of suicidal thoughts or actions.'
Scotsman
an hour ago
- Scotsman
signs and symptoms to look out for
This article contains affiliate links. We may earn a small commission on items purchased through this article, but that does not affect our editorial judgement. Cases of Covid have increased by 10.1% 🤧 Sign up to our daily newsletter Sign up Thank you for signing up! Did you know with a Digital Subscription to Edinburgh News, you can get unlimited access to the website including our premium content, as well as benefiting from fewer ads, loyalty rewards and much more. Learn More Sorry, there seem to be some issues. Please try again later. Submitting... 13 cases of a new Covid strain have been detected in the UK. NB.1.8.1 was first detected in January 2025 and originates from the Omicron variant. The World Health Organisation (WHO) have confirmed it is a variant under monitoring (VUM). Cases of Covid have increased 10.1% according to latest figures from UK Health and Security Agency (UKHSA). Cases of a new Covid variant have been detected in the UK. NB.1.8.1 has already caused a spike in infections and hospitalisations in China and has been identified in 22 countries, with the WHO confirming they have classed it is a 'variant under monitoring'. There have been many different types of variants and subvariants of Covid since the pandemic. NB.1.8.1 is the latest on the scene after the emergence of LP.8.1., which is the most dominant variant in the UK. Advertisement Hide Ad Advertisement Hide Ad Covid infections have been on the rise in the UK, with latest data from UKHSA which revealed up to the week of May 28, cases had increased by 10.1%, up 103 to 1,124. Here's everything you need to know about how many cases of the new variant are in the UK and what symptoms to look out for. There have been 13 cases recorded of the new Covid variant in the UK. | Pexels What is the new Covid strain NB.1.8.1? First detected on January 22, 2025, the new Covid strain, NB.1.8.1 originates from the omicron variant which saw cases spike in 2023. Despite an increase in cases and hospitalisations in some countries where NB.1.8.1 is widespread, the WHO have revealed that current data does not indicate that it leads to more severe illness than current variants. Advertisement Hide Ad Advertisement Hide Ad WHO have designated it as a 'variant under monitoring', but the overall risk to public health has been posed to be 'low', with current Covid vaccines expected to be effective in protecting vulnerable patients from severe illness. How many cases of new Covid variant have been found in the UK? The UKHSA confirmed that there have been 13 cases of NB.1.8.1 found in the UK. Cases of Covid, in the week up to May 28, had increased by 10.1%, up 103 to 1,124, whilst deaths also increased by 5.9% and hospitalisations were up 3.5%. Advertisement Hide Ad Advertisement Hide Ad What are the symptoms of the new Covid variant in the UK? Despite the many different variants, the symptoms of Covid have remained the same. The NHS explain Covid symptoms can include: a high temperature or shivering (chills) a new, continuous cough a loss or change to your sense of smell or taste shortness of breath feeling tired or exhausted an aching body a headache a sore throat a blocked or runny nose loss of appetite diarrhoea feeling sick or being sick Symptoms of Covid are very similar to symptoms of other illnesses, such as colds and flu, which is why if you suspect you have Covid it's important to take a test to confirm or rule out the infection. Most people who have Covid tend to feel better after a few weeks, but it can take longer to recover, with some people experiencing a more serious reaction and prolonged symptoms. 🧪 Boots COVID-19 Test Kits While free testing is no longer widely available, Boots continues to offer a range of COVID-19 lateral flow kits for home use, with results in under 30 minutes. Advertisement Hide Ad Advertisement Hide Ad They're available individually or in multipacks, with options for general use, travel, or workplace settings. If you have a health story to share with us, we'd love to hear from you. You can now send your stories to us online via YourWorld at It's free to use and, once checked, your story will appear on our website and, space allowing, in our newspapers.
Daily Mirror
2 hours ago
- Daily Mirror
Seven symptoms you need to look out for as doctors issue Covid warning
A new variant now spreading across Europe and multiple other continents could leave people with a host of unpleasant symptoms - that don't feel like classic Covid Health officials have warned that people could experience a host of nasty and unusual symptoms if they contract the latest Coronavirus strain. The new variant, named NB.1.8.1, was designated a "SARS-CoV-2 variant under monitoring (VUM)" on May 23, one of six emerging variants currently under WHO monitoring. As of this month, it has crossed multiple continents, with cases flagged in the UK and Ireland in Europe, and further afield in the US and Australia. People have been urged to stay at home for days on end if they find they have symptoms of the new Covid variant, which are a far cry from the classic flu-like signs of their predecessors. While early signs of Covid once included symptoms like a severe cough, sore throat and high fever, NB.1.8.1 is felt most acutely in the gastrointestinal tract. Symptoms of the variant include: Nausea Vomiting Diarrhoea Heartburn Bloating Constipation Abdominal pain Dr Lara Herrero, associate professor and virology research leader at Griffith University in Australia, explained in an article posted on The Conversation that the variant appears to be spreading faster than its predecessors. Of those, Dr Herrero said, it is most similar to subvariants of the Omicron lineage. She said: 'The evidence so far suggests NB.1.8.1 may spread more easily and may partially sidestep immunity from prior infections or vaccination. 'Reports suggest symptoms of NB.1.8.1 should align closely with other Omicron subvariants." The WHO has said the same, stating in its report that the variant has obtained a series of mutations that allow it both to spread easier and potentially evade antibody protections afforded to people by previous infections. The organisation explained: "Spike mutations at position 445 have been shown to enhance binding affinity to hACE2, which could increase the variant's transmissibility." It adds: "Mutations at position 435 shown to reduce the neutralisation potency of class 1 andclass 1/4 antibodies, and mutations at position 478 shown to enhance the evasion of Class 1/2 antibodies." People who exhibit any symptoms have been told to stay indoors by the UK Health Security Agency (UKHSA) which advises people to "avoid contact with vulnerable people and stay at home if possible" for 48 hours.
